Leukemia, Myeloid: all 2,432 studies
Page 22 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Autologous Stem Cell Transplants for Chronic Myelogenous LeukemiaWithdrawnNCT00446173Phase 2
- Registration of Children With CML and Treatment With ImatinibStatus unknownNCT00445822
- Effectiveness of Protected Environment Rooms for AML and MDSTerminatedNCT00443300
- Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AMLTerminatedNCT00430443Phase 1
- Natural History Study of Patients With Chronic Myelogenous LeukemiaCompletedNCT00429910
- Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT00428909Phase 1
- Timed-Sequential Induction in CBF-AMLCompletedNCT00428558Phase 3
- GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid MalignanciesCompletedNCT00426205Not applicable
- Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)CompletedNCT00422890Phase 3
- Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing ChemotherapyCompletedNCT00413439Phase 2/3
- Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or IntolerantNo longer availableNCT00413270
- Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid LeukemiaCompletedNCT00401739Phase 1
- A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous LeukemiaCompletedNCT00400673Phase 2
- AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDSWithdrawnNCT00396968Phase 1/2
- Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00394381Phase 1/2
- Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary AspergillosisCompletedNCT00391014Phase 2
- Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid LeukaemiaCompletedNCT00390897Phase 4
- Treatment of Acute Myeloblastic Leukemia in Younger PatientsCompletedNCT00390715
- A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLCompletedNCT00384228Phase 1/2
- Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseCompletedNCT00383474Phase 1
- Phase I Using Velcade & Idarubicin in Elderly and Relapsed AMLCompletedNCT00382954Phase 1
- MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedNCT00374296Phase 2
- Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AMLCompletedNCT00373373Phase 2
- A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.TerminatedNCT00363025Phase 3
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.CompletedNCT00354146Phase 2
- Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00352677Phase 1
- Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
- Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00345826Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid LeukemiaCompletedNCT00342316Not applicable
- Analyses of Human Samples Collected in Clinical TrialsCompletedNCT00339664
- 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDSCompletedNCT00339196Phase 2
- Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in JapanCompletedNCT00337454Phase 1/2
- PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL TherapyStatus unknownNCT00335868Phase 2
- Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
- L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic SyndromesSuspendedNCT00329498Phase 2
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood TransplantationStatus unknownNCT00328237Phase 2
- Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic PhaseStatus unknownNCT00327262Phase 3
- A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedNCT00324220Phase 1/2
- Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic PhaseWithdrawnNCT00324077Phase 1
- Study of XL999 in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT00322673Phase 2
- AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous LeukemiaCompletedNCT00321581Phase 1
- Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00316953Phase 1
- Study of Bexarotene in Patients With Acute Myeloid LeukemiaCompletedNCT00316030Phase 1
- T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell TransplantationTerminatedNCT00306332Phase 3
- Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionCompletedNCT00305708Phase 1/2
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family DonorStatus unknownNCT00304720Phase 2
- Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With LeukemiaCompletedNCT00304447Phase 4
- Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid LeukemiaNo longer availableNCT00302016
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaTerminatedNCT00301769Phase 1
- Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00301093Phase 1
- Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.CompletedNCT00299780Phase 1
- A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib MesylateCompletedNCT00298987Phase 2
- A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction TherapyWithdrawnNCT00297921Phase 1/2
- Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib TherapyStatus unknownNCT00297570Phase 3
- Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative DisordersCompletedNCT00293410Phase 1
- Use of the MiCK Assay for Apoptosis in AMLCompletedNCT00286845
- Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)CompletedNCT00285259Phase 2
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00283114Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid LeukemiaTerminatedNCT00279773Phase 1
- Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous LeukemiaCompletedNCT00274248Phase 1
- Amonafide in Combination With Cytarabine in Secondary AMLCompletedNCT00273884Phase 2
- Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic MalignanciesCompletedNCT00270881Phase 1/2
- Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)CompletedNCT00266136Phase 3
- Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate TherapyCompletedNCT00264160Phase 2/3
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00258271Phase 1
- Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)CompletedNCT00257647
- Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory LeukemiaCompletedNCT00251368Phase 1
- Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic MalignanciesCompletedNCT00246662Phase 1
- T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)Status unknownNCT00242515Phase 1/2
- Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)CompletedNCT00237120Phase 3
- Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia PatientsCompletedNCT00235560Phase 2
- A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid LeukemiaCompletedNCT00233909Phase 1/2
- Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid LeukaemiaStatus unknownNCT00224614Phase 3
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
- Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
- Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-TStatus unknownNCT00209833Phase 2/3
- Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2
- Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)CompletedNCT00188136Phase 2
- Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00186966Phase 3
- Haploidentical Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00186823Phase 3
- Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent RemissionCompletedNCT00186381Phase 2
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic MalignanciesCompletedNCT00186342Not applicable
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)TerminatedNCT00185523
- AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 YearsCompletedNCT00180102Phase 4
- Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])CompletedNCT00179764Not applicable
- Differentiation Induction in Acute Myelogenous LeukemiaCompletedNCT00175812Phase 1/2
- Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) ImageStatus unknownNCT00172562
- Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)CompletedNCT00171899Phase 4
- Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) LeukemiaCompletedNCT00167167Not applicable
- Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid LeukemiaWithdrawnNCT00162513Phase 1/2
- Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in IsraelCompletedNCT00159003
- Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"Status unknownNCT00155844
- WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)Status unknownNCT00153582Phase 2
- Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous LeukemiaTerminatedNCT00152594Phase 3